2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy
Standard
2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. / Giesen, Nicola; Sprute, Rosanne; Rüthrich, Maria; Khodamoradi, Yascha; Mellinghoff, Sibylle C; Beutel, Gernot; Lueck, Catherina; Koldehoff, Michael; Hentrich, Marcus; Sandherr, Michael; von Bergwelt-Baildon, Michael; Wolf, Hans-Heinrich; Hirsch, Hans H; Wörmann, Bernhard; Cornely, Oliver A; Köhler, Philipp; Schalk, Enrico; von Lilienfeld-Toal, Marie; COVID-19 guideline panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
In: EUR J CANCER, Vol. 147, 04.2021, p. 154-160.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy
AU - Giesen, Nicola
AU - Sprute, Rosanne
AU - Rüthrich, Maria
AU - Khodamoradi, Yascha
AU - Mellinghoff, Sibylle C
AU - Beutel, Gernot
AU - Lueck, Catherina
AU - Koldehoff, Michael
AU - Hentrich, Marcus
AU - Sandherr, Michael
AU - von Bergwelt-Baildon, Michael
AU - Wolf, Hans-Heinrich
AU - Hirsch, Hans H
AU - Wörmann, Bernhard
AU - Cornely, Oliver A
AU - Köhler, Philipp
AU - Schalk, Enrico
AU - von Lilienfeld-Toal, Marie
AU - COVID-19 guideline panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
N1 - Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - The worldwide spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious coronavirus disease (COVID-19) has posed a unique challenge to medical staff, patients and their families. Patients with cancer, particularly those with haematologic malignancies, have been identified to be at high risk to develop severe COVID-19. Since publication of our previous guideline on evidence-based management of COVID-19 in patients with cancer, research efforts have continued and new relevant data has come to light, maybe most importantly in the field of vaccination studies. Therefore, an update of our guideline on several clinically important topics is warranted. Here, we provide a concise update of evidence-based recommendations for rapid diagnostics, viral shedding, vaccination and therapy of COVID-19 in patients with cancer. This guideline update was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology by critically reviewing the currently available data on these topics applying evidence-based medicine criteria.
AB - The worldwide spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious coronavirus disease (COVID-19) has posed a unique challenge to medical staff, patients and their families. Patients with cancer, particularly those with haematologic malignancies, have been identified to be at high risk to develop severe COVID-19. Since publication of our previous guideline on evidence-based management of COVID-19 in patients with cancer, research efforts have continued and new relevant data has come to light, maybe most importantly in the field of vaccination studies. Therefore, an update of our guideline on several clinically important topics is warranted. Here, we provide a concise update of evidence-based recommendations for rapid diagnostics, viral shedding, vaccination and therapy of COVID-19 in patients with cancer. This guideline update was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology by critically reviewing the currently available data on these topics applying evidence-based medicine criteria.
KW - Antiviral Agents/therapeutic use
KW - COVID-19/diagnosis
KW - COVID-19 Testing/methods
KW - COVID-19 Vaccines/therapeutic use
KW - Evidence-Based Medicine/standards
KW - Germany/epidemiology
KW - Hematologic Neoplasms/diagnosis
KW - Hematology/organization & administration
KW - Humans
KW - Immunization, Passive/methods
KW - Infectious Disease Medicine/organization & administration
KW - Medical Oncology/organization & administration
KW - Neoplasms/diagnosis
KW - SARS-CoV-2/immunology
KW - Societies, Medical/standards
KW - Vaccination/methods
KW - Virus Shedding/physiology
KW - COVID-19 Serotherapy
U2 - 10.1016/j.ejca.2021.01.033
DO - 10.1016/j.ejca.2021.01.033
M3 - SCORING: Journal article
C2 - 33676266
VL - 147
SP - 154
EP - 160
JO - EUR J CANCER
JF - EUR J CANCER
SN - 0959-8049
ER -
